Loading...

Clinical Practice Guidelines

Non-alcoholic fatty liver disease: A patient guideline

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.
Read more

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

Non-invasive tests are increasingly being used to improve thediagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.
Read more

EASL recommendations on treatment of Hepatitis C 2020

This final update of the EASL Recommendations on Treatment of Hepatitis C series is intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process, by describing the current optimal management of patients with acute and chronic HCV infections.
Read more

Occupational liver diseases

Summary A variety of chemicals have been linked to occupational liver diseases, including several solvents and mixtures thereof, pesticides, and metals. Workplace exposures have been associated with virtually the entire spectrum of acute and chronic liver diseases. However, their prevalence…

Read more

Drug-Induced Liver Injury EASL Guideline

The focus of this EASL Guideline is idiosyncratic Drug-Induced Liver Injury (DILI). However, it is important to recognise that DILI is traditionally classified as intrinsic (or direct) vs. idiosyncratic. Intrinsic DILI is typically dose-related and occurs in a large proportion of individuals exposed to the drug (predictable) and onset is within a short time span (hours to days). Idiosyncratic DILI is usually not dose-related. Although a dose threshold of 50–100 mg/day is usually required. It occurs in only a small proportion of exposed individuals (unpredictable) and exhibits a variable latency to onset of days to weeks.
Read more

Nutrition in Chronic Liver Disease EASL Guideline

These EASL Guidelines for Clinical Practice review the present knowledge in the field of Nutrition in Chronic Liver Disease and promote further research on this topic. Screening, assessment and principles of nutritional management are examined, with recommendations provided in specific settings such as hepatic encephalopathy, cirrhotic patients with bone disease, patients undergoing liver surgery or transplantation and critically ill cirrhotic patients.
Read more

Treatment of Hepatitis C – 2018 EASL Recommendations

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. As a result, worldwide there are approximately 71 million chronically infected individuals. Clinical care for patients with HCV-related liver disease is advancing considerably. Most importantly thanks to an enhanced understanding of the pathophysiology of the disease. And also because of developments in diagnostic procedures and improvements in therapy and prevention. EASL Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards.
Read more

Hepatocellular Carcinoma EASL Guidelines

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepato-cellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Read more

Hepatitis E Virus Infection EASL Guideline

Hepatitis E Virus Infection (HEV) is a significant cause of morbidity and mortality, representing an important global health problem. Our understanding of HEV has changed completely over the past decade. Previously, the common thought was that HEV was limited to certain developing countries. We now know that HEV is endemic in most high-income countries and is largely a zoonotic infection. The focus of this Clinical Practice Guideline will be on HEV genotype 3 (and 4). This is due to the paradigm shift in our understanding of zoonotic HEV.  And also because locally acquired HEV is now the commonest cause of acute viral hepatitis in many European countries.
Read more

Management of Decompensated Cirrhosis EASL Guideline

EASL Guideline on Management of Decompensated Cirrhosis. The natural history of cirrhosis is characterized by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first Guideline on the Management of Decompensated Cirrhosis.
Read more
Share
Back To Top